Finance

Lists
B1SX34:BVMF
Boston Scientific Corp Brazilian Depositary Receipt
53,34 BRL
0,00%
(0,00) 1D
9-окт., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for B1SX34...
Open
52,72 BRL
High
53,34 BRL
Low
52,50 BRL
Mkt. cap
63,53 млд
Avg. vol.
1,02 миң
Volume
67,00
52-wk high
140,91 BRL
52-wk low
50,29 BRL
Shares outstanding
1,45 млд
No. of employees
59 миң
Open
52,72 BRL
High
53,34 BRL
Low
52,50 BRL
Mkt. cap
63,53 млд
Avg. vol.
1,02 миң
Volume
67,00
52-wk high
140,91 BRL
52-wk low
50,29 BRL
Shares outstanding
1,45 млд
No. of employees
59 миң
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp Brazilian Depositary Receipt
CEOMichael F. Mahoney
Employees59 миң
Founded1979-ж., 29-июн.
HeadquartersМарлборо, Массачусетс, Америка Кошмо Штаттары
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
5,06 млд
5,29 млд
5,20 млд
5,44 млд
Cost of goods sold
1,54 млд
1,61 млд
1,60 млд
1,61 млд
Cost of revenue
1,54 млд
1,61 млд
1,60 млд
1,61 млд
Research and development expenses
514,00 млн
569,00 млн
516,00 млн
554,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 млд
1,83 млд
1,78 млд
1,80 млд
Operating expense
2,48 млд
2,63 млд
2,53 млд
2,59 млд
Total operating expenses
4,02 млд
4,24 млд
4,13 млд
4,20 млд
Operating income
1,05 млд
1,04 млд
1,07 млд
1,25 млд
Other non operating income
-16,00 млн
28,00 млн
28,00 млн
-6,00 млн
EBT including unusual items
938,00 млн
700,00 млн
1,16 млд
1,06 млд
EBT excluding unusual items
935,00 млн
1,01 млд
999,00 млн
1,14 млд
Income tax expense
183,00 млн
30,00 млн
-176,00 млн
155,00 млн
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 млн
672,00 млн
1,34 млд
907,00 млн
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 млн
-
11,00 млн
Interest expense
-87,00 млн
-90,00 млн
-90,00 млн
-96,00 млн
Net interest expenses
-87,00 млн
-61,00 млн
-90,00 млн
-85,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 млд
1,41 млд
1,42 млд
1,60 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору